ʻImi hou no ka mālama ʻana i ka maʻi maʻi pancreatic

A HOLD Hoʻokuʻu ʻole 8 | eTurboNews | eTN
Avatar o Linda Hohnholz
i kakauia ma Linda Hohnholz

Ua hoʻolaha ʻo Loki Therapeutics i kēia lā i nā puke noiʻi ma ka puke pai, "Science Translational Medicine", e hōʻike ana i ka hiki o AWAKE-LM-TT i ka mālama ʻana i ka maʻi maʻi pancreatic. ʻO AWAKE-LM-TT, ka mea i hoʻomohala ʻia e Claudia Gravekamp, ​​Ph.D., Loki's Co-Founder a me Associated Professor of Microbiology & Immunology ma Albert Einstein School of Medicine, hoʻohana i ka lāʻau lapaʻau o ka wā kamaliʻi no ka maʻi tetanus e hoʻoulu i kahi pale ikaika a wikiwiki hoʻi. pane i nā maʻi koko paʻa a me nā metastases e hōʻike ana i nā antigens tetanus.

ʻO ka manuscript i kapa ʻia, "Listeria Delivers Tetanus Toxoid Protein to Pancreatic Tumors and Induces Cancer Cell Death in Mice," a i kākau pū ʻia e Dr. Gravekamp, ​​Ph.D., e wehewehe ana i ka noiʻi e pili ana i kahi ala hou no ka mālama ʻana i ka maʻi pancreatic kahi e loaʻa ai ka Listeria monocytogenes. hoʻohana ʻia e hāʻawi pololei i nā protein tetanus toxoid (TT) immunogenic loa i loko o nā pūnaewele tumor. ʻO kēia hāʻawi ʻana, Listeria-TT, ua hōʻike ʻia e kiʻi i kahi pane kūlohelohe, e hoʻāla ana i ka tetanus toxoid-specific memory T cell e pepehi i ka pancreatic ductal adenocarcinoma (PDAC) tumor cell i nā ʻiole. I ka hui pū ʻana me ka gemcitabine (Listeria-TT + GEM), ua ʻike nā mea noiʻi i ka hōʻemi ʻana o 80% o ke kaumaha o ka maʻi maʻi PDAC a me ka hōʻemi ʻana o 87% o nā metastases me ka piʻi ʻana o ke ola ʻana e 40% i hoʻohālikelike ʻia me nā ʻiole i hoʻopaʻa ʻole ʻia, e hōʻike ana e hiki ke hoʻomanaʻo ʻia nā antigens hoʻomanaʻo Listeria. he mea ʻē aʻe i ka immunotherapy maʻi maʻi neoantigen-mediated.

Ua ʻōlelo ʻo Loki Co-founder a me CEO Chris Bradley, "ʻO kēia haʻawina ka hopena o ka hau hau i ka wā e ʻike ai a loaʻa ai nā lāʻau lapaʻau kūpono e mālama i nā maʻi maʻi paʻakikī. He paʻakikī ka ʻike ʻana i ka maʻi maʻi pancreatic i ka wā mua, ʻoi aku ka paʻakikī o ka loaʻa ʻana o kahi lāʻau lapaʻau, no ka mea, ʻike pinepine ʻia ia ma kahi pae kiʻekiʻe a hope paha. Hōʻike kēia noiʻi i ka mana nui o ka AWAKE-LM-TT o Loki ma ke ʻano he lapaʻau hou no ka maʻi maʻi pancreatic i hāʻawi ʻia i kona hiki ke hoʻohana i ka lāʻau o ka wā kamaliʻi no ka toxoid tetanus e hoʻohua ai i ka pane kūlohelohe ikaika a me nā metastases e hōʻike ana i nā antigens tetanus.

Ua ʻōlelo ʻo Dr. Gravekamp, ​​"Ma muli o kēia noiʻi, loaʻa iā mākou kahi hoʻolālā hou ʻaʻole hiki ke lilo i immunotherapy kūleʻa i ka mālama ʻana i ka maʻi maʻi pancreatic, akā nā maʻi maʻi ʻē aʻe kekahi. He mea paʻakikī loa ka mālama ʻana i nā ʻōpū pancreatic i kēlā, i ka ʻōnaehana pale, ʻaʻole ʻike ʻia kēia mau maʻi ʻaʻai 'haole' no ka huki ʻana i ka manaʻo o ka ʻōnaehana pale a hiki ke hoʻopaʻa pinepine i nā pane kūlohelohe e kū mai. ʻO kā mākou ala e hana ai i kēia mau maʻi 'anuʻu' immunologically i wela no ka ʻōnaehana pale e hoʻouka a luku.

Ke hoʻomākaukau nei ʻo Loki e waiho i kahi noi Investigational New Drug (IND) me ka US Food & Drug Administration no kahi papahana lapaʻau mua i loko o ke kanaka e noiʻi ana iā AWAKE-LM-TT i ka mālama ʻana i ka maʻi maʻi pancreatic. I ka loaʻa ʻana o ka ʻae FDA no ka IND, manaʻo ʻo Loki e hoʻomaka i kahi hoʻokolohua lapaʻau Phase 1 i ka hapa ʻelua o 2022.

No ka mea kākau

Avatar o Linda Hohnholz

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...